BVF Inc. IL Buys 275,105 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

BVF Inc. IL boosted its stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 8.6% during the fourth quarter, Holdings Channel.com reports. The fund owned 3,479,022 shares of the company’s stock after purchasing an additional 275,105 shares during the quarter. Structure Therapeutics comprises 8.2% of BVF Inc. IL’s investment portfolio, making the stock its 4th biggest position. BVF Inc. IL owned about 0.06% of Structure Therapeutics worth $241,966,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. ACT Capital Management LLC acquired a new stake in Structure Therapeutics in the 4th quarter valued at $2,678,000. Schonfeld Strategic Advisors LLC acquired a new stake in Structure Therapeutics in the 4th quarter valued at $607,000. Burkehill Global Management LP acquired a new stake in Structure Therapeutics in the 4th quarter valued at $4,173,000. J. Goldman & Co LP acquired a new stake in Structure Therapeutics in the 4th quarter valued at $946,000. Finally, Cetera Investment Advisers acquired a new stake in Structure Therapeutics in the 4th quarter valued at $459,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Trading Up 4.9%

Shares of GPCR stock opened at $45.00 on Thursday. The company’s 50-day moving average price is $43.09 and its 200-day moving average price is $57.53. The stock has a market cap of $3.20 billion, a price-to-earnings ratio of -51.72 and a beta of -1.35. Structure Therapeutics Inc. Sponsored ADR has a twelve month low of $15.80 and a twelve month high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.04. As a group, equities research analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -1.64 EPS for the current year.

Wall Street Analysts Forecast Growth

GPCR has been the topic of a number of research analyst reports. Wolfe Research started coverage on shares of Structure Therapeutics in a research note on Thursday, March 26th. They issued a “peer perform” rating on the stock. HC Wainwright lowered their target price on shares of Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating on the stock in a research note on Thursday, June 11th. Canaccord Genuity Group started coverage on shares of Structure Therapeutics in a research note on Monday, April 27th. They set a “buy” rating and a $101.00 target price on the stock. William Blair reaffirmed an “outperform” rating on shares of Structure Therapeutics in a research note on Monday, March 16th. Finally, Wall Street Zen cut shares of Structure Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $106.75.

Structure Therapeutics Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.